The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

By Akin Akinc, M. Maier, M. Manoharan, Kevin Fitzgerald, M. Jayaraman, Scott A. Barros, S. Ansell, Xinyao Du, M. Hope, T. D. Madden and 8 more. Nature Nanotechnology, 2019

1,342 citations recorded by the source corpus.

Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/37aa77b03e43f734f67ff0f3db5152aa4cf9d5f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Manoharan
2. Martin Egli

Citations in the corpus

• Therapeutic Nanoparticles and Their Targeted Delivery Applications (2020, background): “Lipid-based (Non-liposoma) Onpattro ® Lipid nanoparticles Transthyretin targeted siRNA Transthyretin-mediated amyloidosis FDA 2018 [96]”
• Smart nanoparticles for cancer therapy (2023, background): “314 Hyaluronic acid has been attached to lipid nanoparticles by Cohen et al. for the treatment of gliomas.”
• Chemistry, structure and function of approved oligonucleotide therapeutics (2023, methodology): “The first siRNA for hATTR treatment, ONPATTRO was approved in 2018 for the treatment of the polyneuropathy of hATTR mediated amyloidosis in adults (49).”